A study published in Baylor University Medical Center Proceedings found that 93% of respondents believed this skill to be very important, yet only 43% felt they had the right training to effectively do so. Despite methods like SPIKES and the ABCDE system, many oncologists still struggle with this skill and with the pandemic still hanging around, it’s a case of “bad news” all around. How do you handle it?

In what is believed to be the most comprehensive molecular characterization to date of HPV-negative head and neck squamous cell carcinomas (HNSCCs), researchers have clarified the contribution of key cancer-associated genes, proteins and signaling pathways in these cancers, while proposing possible new treatment avenues.

According to new research from investigators with the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy, a microbe found in the colon and commonly associated with the development of colitis and colon cancer may also play a role in the development of some breast cancers.

This drug was first approved in the US in the 1970s for anesthesia and pain relief, and last year, the FDA approved it for patients with major depression that are treatment resistant. If you said ketamine, you’re correct, and because more than 30% of patients are resistant to SSRIs, finding an effective treatment for major depressive disorder is challenging. Could this old drug be the answer?

COVID-19 has led to severe mental repercussions, which is made worse when considering what types of challenges people were having before the pandemic even hit. Considering this, it’s a good time to review the drug-drug interactions (DDIs) psychotropic drugs can have with each other, not to mention other drugs for the most common conditions. Here are 20 such interactions for your review. 

The International Duration of Adjuvant Chemotherapy (IDEA) collaboration investigated whether 3-month adjuvant chemotherapy treatment can be given for colon cancer without compromising efficacy, as six-month adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin doublet is an option for high-risk stage II colon cancer. Here are the results.